Exagen (XGN) President and CEO John Aballi Sells $270K of Stock
Key Points
- President and CEO John Aballi sold 34,294 shares of Exagen Inc. on October 16, 2026, at a price of $7.87 per share.
- After the trade, John Aballi holds 805,540 $XGN shares, down 4.08% from before the trade.
- Institutional investors like FourWorld Capital Management and Nano Cap New Millennium Growth Fund adjusted their stakes in earlier periods.
- Exagen is scheduled to release its next financial results on November 10, 2026.
Since the trade, $XGN is down 3.8% to date (from the $7.72 close on Oct 16, 2026).
Get Exagen text alerts
We text you when insiders, Congress, analysts or big funds move on $XGN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Exagen Inc. alert may contain errors. Disclosures
Exagen Inc. President and CEO John Aballi sold 34,294 shares of the company on October 16, 2026. The transaction was revealed in a Form 4 filed with the Securities and Exchange Commission.
XGN
Exagen Inc.
Inside John Aballi's Exagen Trade
Aballi executed the sale at a price of $7.87 per share, bringing the total value of the transaction to $269,790.90. Following the sale, he holds 805,540 shares of stock, marking a 4.08% cut to his direct holdings. This trade was not carried out under a pre-arranged Rule 10b5-1 trading plan. The stock closed at $7.72 on the day of the transaction.
Other Institutional Activity in Exagen
Other large funds made notable adjustments to their holdings in Exagen earlier in the year. Wexford Capital LP held steady with 792,855 shares worth about $5,890,912. Nano Cap New Millennium Growth Fund L P grew its holdings by 89,977 shares, ending with 675,000 shares worth about $5,015,249. FourWorld Capital Management, LLC increased its stake by 156,578 shares to finish with 596,528 shares valued at approximately $4,432,202. Meanwhile, Silvercrest Asset Management Group, LLC trimmed its holdings by 23,129 shares, leaving it with 514,761 shares worth about $3,824,674. Kennedy Capital Management, LLC also reduced its holdings by 8,589 shares, closing the period with 485,048 shares valued at roughly $3,603,906.
Exagen Inc. Stock Down 11.7%
Exagen shares recently traded around $7.43 as of October 19, 2026, putting the price about 3.8% below the event-day close of $7.72.
Recent Earnings
Exagen generated $71,122,000 in trailing twelve-month revenue with an EPS of -$0.82. The company reports an annual revenue growth rate of 15.9%, alongside negative returns and profit margins. Its next earnings release is scheduled for November 10, 2026.
Insider Buying and Selling at Exagen Inc.
Earlier insider moves included Chief Financial Officer Jeffrey G. Black selling 20,614 shares on September 1, 2026, at $7.22 per share. Earlier in June, insiders Chas Mckhann, Scott Kahn, and Frank Stokes each acquired 37,500 shares.
Analysts Set New Price Targets
Wall Street firms have remained active on the stock, with TD Cowen recently maintaining a buy rating and raising its price target to $11.00 on October 13, 2026.
About Exagen Inc.
Exagen Inc. creates and sells specialized diagnostic testing products under the AVISE brand. The company focuses on helping doctors diagnose and monitor complex autoimmune conditions, such as rheumatoid arthritis and systemic lupus erythematosus.
Bottom Line
Investors are watching for the upcoming earnings report on November 10, 2026, to gauge the company's financial progress. Future Form 4 filings will show whether executive selling continues.
Related Filing Alerts
Source: John Aballi's Form 4 filing on $XGN (Oct 16, 2026). Written by software, not financial advice. How we make alerts